



Are you living with Friedreich ataxia? Do you have symptoms that affect your balance and daily activities?

We are looking for people between the ages of 18 and 55 years who have Friedreich ataxia (FRDA).

The TAK-831-1501 Study is looking at a potential new medication (investigational medication) to see how safe it is and how well it works for people with FRDA.

To participate, you must:

- have genetic confirmation of FRDA
- be able to complete the timed 9-hole peg test
- be willing to keep your medications stable throughout the study
- use an acceptable form of contraception throughout the study.

About the study

- Approximately 65 people in 6 locations across the United States will participate in this study.
- If you are eligible and you decide to join the study, your participation will last for up to 126 days (18 weeks).
- You will be asked to complete about 6 visits to the study center and several phone calls.

You will be randomly assigned to get either the investigational medication or a placebo. The placebo looks the same as the investigational medication but has no actual medication in it. You will have a 6-in-10 (60%) chance of getting the investigational medication.

- You will take either the investigational medication or placebo as tablets, twice a day for 12 weeks.
- You may not directly benefit from participating in this study, but you and other participants may make an important contribution to advancing the understanding and treatment of FRDA.

All study-related care and study medication will be provided at no cost. You may also be reimbursed for your travel expenses.

Want to know more?

To learn more about the TAK-831-1501 Study, please contact:

